Britain approves AstraZeneca’s Covid-19 treatment amid rising cases
Britain approved AstraZeneca’s (NYSE: AZN) antibody-based Covid-19 treatment for adults with poor immune system, said the country’s medicines regulator on Thursday
• The Covid-19 treatment reduces risk of developing symptomatic Covid-19 by 77%,
• WHO warned nations this week that a global rise in Covid-19 infections could be big problem
Britain approved AstraZeneca’s (NYSE: AZN) antibody-based Covid-19 treatment for adults with poor immune system, said the country’s medicines regulator on Thursday.
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) said the approval for the Covid-19 treatment, Evusheld, was supported by the government’s independent scientific advisory body.
This comes as the World Health Organization warned nations this week that a global rise in Covid-19 infections could be big problem.
The treatment is designed for adults with poor immune system or with a history of reactions to a vaccine. Around 85% of the population in Britain over the age of 12 has been vaccinated with two doses.
"While the COVID-19 vaccines continue to be the first-line defence against COVID-19, we know that some people may not respond adequately to these vaccines,' MHRA chief June Raine said, reported Reuters.
The Covid-19 treatment, Evusheld, contains lab-made antibodies which are present in the body for months to fight the virus if the person is infected.
The MHRA said the treatment reduces risk of developing symptomatic Covid-19 by 77%, according to studies, protecting the individual for at least six months after a single dose.
Picture Credits: Reuters
